{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T19:54:09Z","timestamp":1721937249917},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T00:00:00Z","timestamp":1527292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40618-018-0905-1","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T05:45:35Z","timestamp":1527313535000},"page":"207-215","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?"],"prefix":"10.1007","volume":"42","author":[{"given":"M.","family":"Demirpence","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Guler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sayin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Pekcevik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Turkon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Colak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M.","family":"Ari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Aslanipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. U.","family":"Kocabas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Calan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,26]]},"reference":[{"key":"905_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/sj.bjp.0703601","volume":"131","author":"JJ Maguire","year":"2000","unstructured":"Maguire JJ, Kuc RE, Davenport AP (2000) Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131:441\u2013446. \n                    https:\/\/doi.org\/10.1038\/sj.bjp.0703601","journal-title":"Br J Pharmacol"},{"key":"905_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cne.20845","volume":"495","author":"S J\u00e9gou","year":"2006","unstructured":"J\u00e9gou S, Cartier D, Dubessy C, Gonzalez BJ, Chatenet D, Tostivint H et al (2006) Localization of the urotensin II receptor in the rat central nervous system. J Comp Neurol 495:21\u201336. \n                    https:\/\/doi.org\/10.1002\/cne.20845","journal-title":"J Comp Neurol"},{"key":"905_CR3","doi-asserted-by":"publisher","first-page":"T61","DOI":"10.1530\/JME-13-0274","volume":"52","author":"H Tostivint","year":"2014","unstructured":"Tostivint H, Ocampo Daza D, Bergqvist CA, Quan FB, Bougerol M, Lihrmann I et al (2014) Molecular evolution of GPCRs: somatostatin\/urotensin II receptors. J Mol Endocrinol 52:T61\u2013T86. \n                    https:\/\/doi.org\/10.1530\/JME-13-0274","journal-title":"J Mol Endocrinol"},{"key":"905_CR4","doi-asserted-by":"publisher","first-page":"R1156","DOI":"10.1152\/ajpregu.00706.2009","volume":"298","author":"B Ross","year":"2010","unstructured":"Ross B, McKendy K, Giaid A (2010) Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol 298:R1156\u2013R1172. \n                    https:\/\/doi.org\/10.1152\/ajpregu.00706.2009","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"905_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/1568009616666160621101248","volume":"17","author":"A Federico","year":"2017","unstructured":"Federico A, Zappavigna S, Dallio M, Misso G, Merlino F, Loguercio C et al (2017) Urotensin-II receptor: a double identity receptor involved in vasoconstriction and in the development of digestive tract cancers and other tumors. Curr Cancer Drug Targets 17:109\u2013121. \n                    https:\/\/doi.org\/10.2174\/1568009616666160621101248","journal-title":"Curr Cancer Drug Targets"},{"key":"905_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2004.03.023","volume":"176","author":"N Bousette","year":"2004","unstructured":"Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A (2004) Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176:117\u2013123. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosis.2004.03.023","journal-title":"Atherosclerosis"},{"key":"905_CR7","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1161\/01.HYP.0000184226.99196.b5","volume":"46","author":"T Watanabe","year":"2005","unstructured":"Watanabe T, Suguro T, Kanome T, Sakamoto Y-I, Kodate S, Hagiwara T et al (2005) Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46:738\u2013744. \n                    https:\/\/doi.org\/10.1161\/01.hyp.0000184226.99196.b5","journal-title":"Hypertension"},{"key":"905_CR8","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.3748\/wjg.v22.i25.5769","volume":"22","author":"Y-Y Li","year":"2016","unstructured":"Li Y-Y, Shi Z-M, Yu X-Y, Feng P, Wang X-J (2016) Urotensin II-induced insulin resistance is mediated by NADPH oxidase-derived reactive oxygen species in HepG2 cells. World J Gastroenterol 22:5769. \n                    https:\/\/doi.org\/10.3748\/wjg.v22.i25.5769","journal-title":"World J Gastroenterol"},{"key":"905_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.regpep.2009.01.004","volume":"154","author":"HX Wang","year":"2009","unstructured":"Wang HX, Zeng XJ, Liu Y, Wang J, Lu LQ, Hao G et al (2009) Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse. Regul Pept 154:85\u201390. \n                    https:\/\/doi.org\/10.1016\/j.regpep.2009.01.004","journal-title":"Regul Pept"},{"key":"905_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/cs1040001","volume":"104","author":"K Totsune","year":"2003","unstructured":"Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O (2003) Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 104:1\u20135. \n                    https:\/\/doi.org\/10.1042\/cs1040001","journal-title":"Clin Sci"},{"key":"905_CR11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1097\/01.hjh.0000125452.28861.f1","volume":"22","author":"BMY Cheung","year":"2004","unstructured":"Cheung BMY, Leung R, Man YB, Wong LYF (2004) Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22:1341\u20131344","journal-title":"J Hypertens"},{"key":"905_CR12","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3109\/09513590.2013.824962","volume":"29","author":"\u00d6 Yilmaz","year":"2013","unstructured":"Yilmaz \u00d6, Calan O, Kume T, Calan M (2013) The relationship of urotensin II with insulin resistance and hs-CRP in patients having PCOS. Gynecol Endocrinol 29:970\u2013973. \n                    https:\/\/doi.org\/10.3109\/09513590.2013.824962","journal-title":"Gynecol Endocrinol"},{"key":"905_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.peptides.2014.03.004","volume":"55","author":"H Al Kindi","year":"2014","unstructured":"Al Kindi H, Hafiane A, You Z, Albanese I, Pilote L, Genest J et al (2014) Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease. Peptides 55:151\u2013157. \n                    https:\/\/doi.org\/10.1016\/j.peptides.2014.03.004","journal-title":"Peptides"},{"key":"905_CR14","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.77.8.5021","volume":"77","author":"D Pearson","year":"1980","unstructured":"Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS et al (1980) Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77:5021\u20135024","journal-title":"Proc Natl Acad Sci USA"},{"key":"905_CR15","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMra062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S (2006) Acromegaly. N Engl J Med 355:2558\u20132573. \n                    https:\/\/doi.org\/10.1056\/NEJMra062453","journal-title":"N Engl J Med"},{"key":"905_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.peptides.2007.12.015","volume":"29","author":"MM Malagon","year":"2008","unstructured":"Malagon MM, Molina M, Gahete MD, Duran-Prado M, Martinez-Fuentes AJ, Alcain FJ et al (2008) Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5. Peptides 29:711\u2013720. \n                    https:\/\/doi.org\/10.1016\/j.peptides.2007.12.015","journal-title":"Peptides"},{"key":"905_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102\u2013152. \n                    https:\/\/doi.org\/10.1210\/er.2002-0022","journal-title":"Endocr Rev"},{"key":"905_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1210\/edrv-15-5-555","volume":"15","author":"L Sacc\u00e0","year":"1994","unstructured":"Sacc\u00e0 L, Cittadini A, Fazio S (1994) Growth hormone and the heart. Endocr Rev 15:555\u2013573. \n                    https:\/\/doi.org\/10.1210\/edrv-15-5-555","journal-title":"Endocr Rev"},{"key":"905_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-128-4-199802150-00002","volume":"128","author":"HN Hodis","year":"1998","unstructured":"Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH et al (1998) The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128:262\u2013269","journal-title":"Ann Intern Med"},{"key":"905_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ihj.2015.08.005","volume":"68","author":"K Meenakshi","year":"2016","unstructured":"Meenakshi K, Rajendran M, Srikumar S, Chidambaram S (2016) Epicardial fat thickness: a surrogate marker of coronary artery disease\u2014assessment by echocardiography. Indian Heart J 68:336\u2013341. \n                    https:\/\/doi.org\/10.1016\/j.ihj.2015.08.005","journal-title":"Indian Heart J"},{"key":"905_CR21","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1161\/01.CIR.0000099542.57313.C5","volume":"108","author":"T Mazurek","year":"2003","unstructured":"Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H et al (2003) Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108:2460\u20132466. \n                    https:\/\/doi.org\/10.1161\/01.CIR.0000099542.57313.C5","journal-title":"Circulation"},{"key":"905_CR22","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141\u20133148. \n                    https:\/\/doi.org\/10.1210\/jc.2009-2670","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 4","key":"905_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.17.S4.1","volume":"17","author":"L Katznelson","year":"2011","unstructured":"Katznelson L, Atkinson JLD, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK et al (2011) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u20142011 update. Endocr Pract 17(Suppl 4):1\u201344","journal-title":"Endocr Pract"},{"key":"905_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000343145","volume":"34","author":"P-J Touboul","year":"2012","unstructured":"Touboul P-J, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N et al (2012) Mannheim carotid intima-media thickness and plaque consensus (2004\u20132006\u20132011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, B. Cerebrovasc Dis 34:290\u2013296. \n                    https:\/\/doi.org\/10.1159\/000343145","journal-title":"Cerebrovasc Dis"},{"key":"905_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2009.10.013","author":"G Iacobellis","year":"2009","unstructured":"Iacobellis G, Willens HJ (2009) Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr. \n                    https:\/\/doi.org\/10.1016\/j.echo.2009.10.013","journal-title":"J Am Soc Echocardiogr"},{"key":"905_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.amjhyper.2006.08.001","volume":"20","author":"T Suguro","year":"2007","unstructured":"Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T et al (2007) Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20:211\u2013217. \n                    https:\/\/doi.org\/10.1016\/j.amjhyper.2006.08.001","journal-title":"Am J Hypertens"},{"key":"905_CR27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1751-7176.2010.00336.x","volume":"12","author":"D Gruson","year":"2010","unstructured":"Gruson D, Rousseau MF, Ketelslegers J-M, Hermans MP (2010) Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J Clin Hypertens (Greenwich) 12:653\u2013660. \n                    https:\/\/doi.org\/10.1111\/j.1751-7176.2010.00336.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"905_CR28","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1161\/ATVBAHA.112.252973","volume":"32","author":"Z You","year":"2012","unstructured":"You Z, Genest J, Barrette P-O, Hafiane A, Behm DJ, D\u2019Orleans-Juste P et al (2012) Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequelae in mice. Arterioscler Thromb Vasc Biol 32:1809\u20131816. \n                    https:\/\/doi.org\/10.1161\/ATVBAHA.112.252973","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"905_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1042\/CS20080014","volume":"115","author":"T Suguro","year":"2008","unstructured":"Suguro T, Watanabe T, Kodate S, Xu G, Hirano T, Adachi M et al (2008) Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin Sci 115:327\u2013334. \n                    https:\/\/doi.org\/10.1042\/CS20080014","journal-title":"Clin Sci"},{"key":"905_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.amjcard.2012.08.044","volume":"111","author":"SD Pierdomenico","year":"2013","unstructured":"Pierdomenico SD, Pierdomenico AM, Cuccurullo F, Iacobellis G (2013) Meta-analysis of the relation of echocardiographic epicardial adipose tissue thickness and the metabolic syndrome. Am J Cardiol 111:73\u201378. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2012.08.044","journal-title":"Am J Cardiol"},{"key":"905_CR31","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.1210\/jc.2005-1087","volume":"90","author":"G Iacobellis","year":"2005","unstructured":"Iacobellis G, Leonetti F (2005) Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab 90:6300\u20136302. \n                    https:\/\/doi.org\/10.1210\/jc.2005-1087","journal-title":"J Clin Endocrinol Metab"},{"key":"905_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/769175","volume":"2013","author":"M Cetin","year":"2013","unstructured":"Cetin M, Cakici M, Polat M, Suner A, Zencir C, Ardic I (2013) Relation of epicardial fat thickness with carotid intima-media thickness in patients with type 2 diabetes mellitus. Int J Endocrinol 2013:1\u20136. \n                    https:\/\/doi.org\/10.1155\/2013\/769175","journal-title":"Int J Endocrinol"},{"key":"905_CR33","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/cen.12356","volume":"80","author":"O Topaloglu","year":"2014","unstructured":"Topaloglu O, Sayki Arslan M, Turak O, Ginis Z, Sahin M, Cebeci M et al (2014) Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules. Clin Endocrinol (Oxf) 80:726\u2013734. \n                    https:\/\/doi.org\/10.1111\/cen.12356","journal-title":"Clin Endocrinol (Oxf)"},{"key":"905_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/cen.13273","volume":"86","author":"A Aulinas","year":"2017","unstructured":"Aulinas A, Crespo I, Vilad\u00e9s D, Leta R, Urgell E, Biagetti B et al (2017) Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly. Clin Endocrinol (Oxf) 86:214\u2013222. \n                    https:\/\/doi.org\/10.1111\/cen.13273","journal-title":"Clin Endocrinol (Oxf)"},{"key":"905_CR35","doi-asserted-by":"publisher","first-page":"e81764","DOI":"10.1371\/journal.pone.0081764","volume":"8","author":"H Peng","year":"2013","unstructured":"Peng H, Zhang M, Cai X, Olofindayo J, Tan A, Zhang Y (2013) Association between human urotensin ii and essential hypertension\u2014a 1:1 matched case-control study. PLoS ONE 8:e81764. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0081764","journal-title":"PLoS ONE"},{"key":"905_CR36","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1213\/01.ANE.0000086723.97421.BC","volume":"97","author":"JP Thompson","year":"2003","unstructured":"Thompson JP, Watt P, Sanghavi S, Strupish JW, Lambert DG (2003) A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg 97:1501\u20131503","journal-title":"Anesth Analg"},{"key":"905_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/eci.12231","volume":"44","author":"A Federico","year":"2014","unstructured":"Federico A, Zappavigna S, Romano M, Grieco P, Luce A, Marra M et al (2014) Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. Eur J Clin Invest 44:285\u2013294. \n                    https:\/\/doi.org\/10.1111\/eci.12231","journal-title":"Eur J Clin Invest"},{"key":"905_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/jcb.22933","volume":"112","author":"P Grieco","year":"2011","unstructured":"Grieco P, Franco R, Bozzuto G, Toccacieli L, Sgambato A, Marra M et al (2011) Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. J Cell Biochem 112:341\u2013353. \n                    https:\/\/doi.org\/10.1002\/jcb.22933","journal-title":"J Cell Biochem"},{"key":"905_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1756-9966-33-48","volume":"33","author":"R Franco","year":"2014","unstructured":"Franco R, Zappavigna S, Gigantino V, Luce A, Cantile M, Cerrone M et al (2014) Urotensin II receptor determines prognosis of bladder cancer regulating cell motility\/invasion. J Exp Clin Cancer Res 33:48. \n                    https:\/\/doi.org\/10.1186\/1756-9966-33-48","journal-title":"J Exp Clin Cancer Res"},{"key":"905_CR40","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.2217\/fon.15.249","volume":"11","author":"O Cobelli De","year":"2015","unstructured":"De Cobelli O, Buonerba C, Terracciano D, Bottero D, Lucarelli G, Bove P et al (2015) Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncol 11:3091\u20133098. \n                    https:\/\/doi.org\/10.2217\/fon.15.249","journal-title":"Future Oncol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-018-0905-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0905-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0905-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T23:06:43Z","timestamp":1568761603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-018-0905-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,26]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s40618-018-0905-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,26]]},"assertion":[{"value":"31 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study adhered strictly to the principles of the Declaration of Helsinki as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The subjects gave their oral and written informed consent before their inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}